Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation
Pharmacological Reports · 2024
DOI: 10.1007/s43440-024-00630-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Reports, 2024. Verfasst von Yana Babii und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland. Hauptthemen laut MEDLINE: Scopolamine, Antidepressive Agents, Depression, Stress, Psychological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Background
The cholinergic system has been increasingly linked to the pathophysiology of mood disorders such as depression, with the potential involvement of nicotinic and/or muscarinic receptors. Conventional antidepressants usually require weeks of daily dosing to achieve a full antidepressant response. In contrast, clinical studies have shown that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, can induce potent and rapid antidepressant effects, requiring only a few days of treatment. This study aimed to examine the suitability of the unpredictable chronic mild stress (UCMS) model of depression to reproduce the above scopolamine antidepressant activity patterns.
Methods
Rapid and sustained antidepressant-like effects were assessed by using the splash test, sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST) in animals undergoing the UCMS procedure and stress-naïve C57BL/6J mice. Western Blotting was used to measure tropomyosin receptor kinase B (TrkB), mammalian target of rapamycin (mTOR), eukaryotic elongation factor (eEF2) and postsynaptic density protein 95 (PSD95) levels.
Results
Scopolamine induced antidepressant-like effects in a dose-dependent manner only after subchronic, but not single, administration in the UCMS model of depression in C57BL/6J mice without affecting locomotor activity. Specifically, scopolamine administered at a dose of 0.3 mg/kg for four consecutive days significantly reversed the UCMS-induced depressive-like behavior, such as apathy, anhedonia, and behavioral despair, while scopolamine, given at the same dose but only once, did not relieve the above symptoms. Scopolamine treatment was accompanied by eEF2 protein dephosphorylation and its subsequent reactivation in the prefrontal cortex (PFC).
Conclusion
Subchronic administration of scopolamine is needed to ameliorate UCMS-induced depressive-like behavior. The suggested mechanism of scopolamine action covers eEF2 protein activity in the PFC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
- Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland. nfpilc@cyf-kr.edu.pl.
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Babii, Y., Pałucha-Poniewiera, A., Rafało-Ulińska, A., Brański, P., & Pilc, A. (2024). Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00630-4
Vancouver
Babii Y, Pałucha-Poniewiera A, Rafało-Ulińska A, Brański P, Pilc A. Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation. Pharmacological Reports. 2024. doi:10.1007/s43440-024-00630-4
BibTeX
@article{Babii2024,
author = {Babii, Yana and Pałucha-Poniewiera, Agnieszka and Rafało-Ulińska, Anna and Brański, Piotr and Pilc, Andrzej},
title = {Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation},
journal = {Pharmacological Reports},
year = {2024},
doi = {10.1007/s43440-024-00630-4}
}
EUVIMED